Huntington's disease

Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics

Volumn , Issue , 2005, Pages 847-860

  Kosinski, Christoph M ^a   Landwehrmeyer, Bernhard ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882357733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544873.058     Document Type: Chapter

References (153)

1. Albin, R. L., Young, A. B. & Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci., 12, 366- 75.
2. Andrew, S. E., Goldberg, Y. P., Kremer, B. et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet., 4, 398- 403.
3. Andrew, S. E., Goldberg, Y. P., Kremer, B. et al. (1994a). Huntington disease without CAG expansion: phenocopies or errors in assignment? Am. J. Hum. Genet., 54, 852-63.
4. Andrew, S. E., Goldberg, Y. P., Theilmann, J., Zeisler, J. & Hayden, M. R. (1994b). A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum. Mol. Genet., 3, 65-7.
5. Ashizawa, T., Wong, L. J., Richards, C. S., Caskey, C. T. & Jankovic, J. (1994). CAG repeat size and clinical presentation in Huntington's disease. Neurology, 44, 1137-43.
6. Bamford, K. A., Caine, E. D., Kido, D. K., Cox, C. & Shoulson, I. (1995). A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology, 45, 1867-73.
7. Barron, L. H., Rae, A., Holloway, S., Brock, D. J. & Warner, J. P. (1994). A single allele fromthepolymorphicCCGrichsequence immediately 3
8. Bauer, P., Laccone, F., Rolfs, A. et al.(2004). Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J.Med. Genet., 41, 230-2.
9. Beal, M. F. (1995). Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol., 38, 357-66.
10. Beenen, N., Buttner, U. & Lange, H.W. (1986). The diagnostic value of eyemovement recordings in patients withHuntington's disease and their offspring. Electroencephalogr. Clin. Neurophysiol., 63, 119-27.
11. Behrens, P. F., Franz, P., Woodman, B., Lindenberg, K. S. & Landwehrmeyer, G. B. (2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain, 125, 1908-22.
12. Bots, G. T. & Bruyn, G.W. (1981). Neuropathological changes of the nucleusaccumbensinHuntington'schorea.ActaNeuropathol. (Berl.), 55, 21-2.
13. Boutell, J. M., Thomas, P., Neal, J. W. et al. (2004). Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet., 1999, 1647.
14. Brandt, J., Strauss, M. E., Larus, J., Jensen, B., Folstein, S. E. & Folstein, M. F. (1984). Clinical correlates of dementia and disability in Huntington's disease. J. Clin. Neuropsychol., 6, 401- 12.
15. Brandt, J., Bylsma, F., Gross, R., Stine, O., Ranen, N. & Ross, C. (1996). Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology, 46, 531-5.
16. Brinkman, R. R., Mezei, M.M., Theilmann, J., Almqvist, E. & Hayden, M. R. (1997). The likelihood of being affected withHuntington disease by a particular age, for a specific CAG size.Am. J. Hum. Genet., 60, 1202-10.
17. Browne, S. E., Ferrante, R. J. & Beal, M. F. (1999). Oxidative stress in Huntington's disease. Brain Pathol., 9, 147-63.
18. Bruyn, G. W. (1979). [Huntington's chorea]. Tijdschr. Ziekenverpl., 32, 101-5.
19. Butters, N., Wolfe, J., Granholm, E. & Martone, M. (1986). An assessment of verbal recall, recognition and fluency abilities in patients with Huntington's disease. Cortex, 22, 11- 32.
20. Bylsma, F. W., Rebok, G. W. & Brandt, J. (1991). Long-term retention of implicit learning in Huntington's disease. Neuropsychologia, 29, 1213-21.
21. Cepeda, C., Ariano, M.A., Calvert, C. R. et al. (2001). NMDAreceptor function in mouse models of Huntington disease. J. Neurosci. Res., 66, 525-39.
22. Cha, J. H. (2000). Transcriptional dysregulation in Huntington's disease. Trends Neurosci., 23, 387-92.
23. Cha, J. H., Kosinski, C. M., Kerner, J. A. et al. (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormalhumanhuntington disease gene. Proc. Natl Acad. Sci. USA, 95(11), 6480-5.
24. Cha, J. H., Frey, A. S., Alsdorf, S. A. et al. (1999). Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. R. Soc. Lond. B Biol. Sci., 354, 981-9.
25. Chen, M., Ona, V. O., Li, M. et al. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease.Nat.Med., 6, 797-801.
26. Chen, S., Ferrone, F. A. & Wetzel, R. (2002). Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl Acad. Sci., USA, 99, 11884-9.
27. Chong, S. S., Almqvist, E., Telenius, H. et al. (1997). Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single spermanalyses. Hum.Mol. Genet., 6, 301-9.
28. Claes, S., Van Zand, K., Legius, E. et al. (1995). Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch. Neurol., 52, 749-53.
29. Critchley, E. M., Clark, D. B. & Wikler, A. (1967). An adult form of acanthocytosis. Trans. Am. Neurol. Assoc., 92, 132-7.
30. Crossman, A. R. (1987). Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience, 21, 1-40.
31. Cummings, C.J. & Zoghbi, H.Y. (2000). Trinucleotiderepeats:mechanisms and pathophysiology. Annu. Rev.Genom.Hum.Genet., 1, 281-328.
32. Curra, A., Agostino, R., Galizia, P., Fittipaldi, F., Manfredi, M. & Berardelli, A. (2000). Sub-movement cueing and motor sequence execution in patients with Huntington's disease. Clin. Neurophysiol., 111, 1184-90.
33. Curtis, A. R., Fey, C., Morris, C. M. et al. (2001). Mutation in the gene encoding ferritin light polypeptide causes dominant adultonset basal ganglia disease. Nat. Genet., 28, 350-4.
34. Danek, A., Tison, F., Rubio, J., Oechsner, M., Kalckreuth, W. & Monaco, A. P. (2001). The chorea of McLeod syndrome. Mov. Disord., 16, 882-9.
35. Davies, S., Turmaine, M., Cozens, B. et al. (1997). Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-48.
36. Davis, M. B., Bateman, D., Quinn, N. P., Marsden, C. D. & Harding, A. E. (1994). Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet, 344, 714-17.
37. de Boo, G., Tibben, A., Hermans, J., Maat, A. & Roos R. A., Davis, M. B., Bateman, D., Quinn, N. P., Marsden, C. D. & Harding, A. E. (1998). Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov. Disord., 13, 96-9.
38. Dedeoglu, A., Kubilus, J. K., Yang, L. et al. (2003). Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenicmice.J.Neurochem., 85, 1359- 67.
39. DiFiglia, M., Sapp, E., Chase, K. et al. (1997). Aggregation of huntingtin in neuronal intranuclear inclusionsanddystrophic neurites in brain. Science, 277, 1990-3.
40. Dunah, A. W., Jeong, H., Griffin, A. et al. (2002). Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-43.
41. Duyao, M., Ambrose, C. & Myers, R. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet., 4, 387-92.
42. Farrer, L. A. (1985). Diabetes mellitus in Huntington disease. Clin. Genet., 27(1), 62-7.
43. Feigin, A., Kieburtz, K., Bordwell, K. et al. (1995). Functional decline in Huntington's disease. Mov. Disord., 10, 211-14.
44. Ferrante, R. J., Andreassen, O. A., Jenkins, B. G. et al. (2000). Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci., 20, 4389-97.
45. Ferrante, R. J., Kubilus, J. K., Lee, J. et al. (2004). Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 9418-27.
46. Folstein, S. E., Jensen, B., Leigh, R. J. & Folstein, M. F. (1983). The measurementof abnormalmovement:methodsdeveloped for Huntington's disease. Neurobehav. Toxicol. Teratol., 5, 605-9.
47. Forno, L. S. & Norville, R. L. (1979). Ultrastructure of the neostriatum in Huntington's and Parkinson's disease. Adv. Neurol., 23, 123-39.
48. Friedlander, R. M. (2003). Apoptosis and caspases in neurodegenerative diseases. N. Engl. J.Med., 348, 1365-75.
49. Garcia Ruiz, P. J., Gomez-Tortosa, E., del Barrio, A. et al. (1997). Senile chorea: a multicenter prospective study. Acta Neurol. Scand., 95, 180-3.
50. Gellera, C., Meoni, C., Castellotti, B. et al. (1996). Errors inHuntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am. J. Hum. Genet., 59, 475-7.
51. Georgiou, N., Phillips, J. G., Bradshaw, J. L., Cunnington, R. & Chiu, E. (1997). Impairments of movement kinematics in patients with Huntington's disease: a comparison with and without a concurrent task. Mov. Disord., 12, 386-96.
52. Goldberg, Y. P., Andrew, S. E., Theilmann, J. et al. (1993). Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. J. Med. Genet., 30, 987-90.
53. Gusella, J. F., Wexler, N. S., Conneally, P. M. et al. (1983). A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 306, 234-8.
54. Gusella, J. F., Tanzi, R. E., Bader, P. I. et al. (1985). Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature, 318, 75-8.
55. Haines, J. L. & Conneally, P.M.(1986). CausesofdeathinHuntington disease as reported on death certificates. Genet. Epidemiol., 3, 417-23.
56. Hardie, R. J., Pullon, H.W., Harding, A. E. et al. (1991). Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain, 114(Pt 1A), 13-49.
57. Hefter, H., Homberg, V., Lange, H. W. & Freund, H. J. (1987). Impairmentof rapidmovementinHuntington's disease.Brain, 110(3), 585-612.
58. Heinsen, H., Strik, M., Bauer, M. et al. (1994). Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol., 88, 320-33.
59. Hickey, M. A. & Chesselet, M.-F. (2003). Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 255-65.
60. Higgins, J. J., Patterson, M. C., Papadopoulos, N. M., Brady, R. O., Pentchev, P. G. & Barton, N. W. (1992). Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology, 42, 194-8.
61. Hockly, E., Richon, V. M., Woodman, B., et al. (2003). Suberoylanilidehydroxamicacid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci., USA, 100, 2041-6.
62. Hoffmann, J. (1888). Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchow's Archiv für Pathol. Anat., 111, 513-48.
63. Holbert, S., Denghien, I., Kiechle, T. et al. (2001). TheGln-Ala repeat transcriptional activatorCA150interacts with huntingtin:neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl Acad. Sci., USA, 98, 1811-16.
64. Huntington, G. (1872). On chorea.Med. Surg. Rep., 26, 317-21.
65. Huntington Study Group (1996). UnifiedHuntington'sDisease Rating Scale: reliability and consistency.Mov.Disord., 11, 136-42.
66. Huntington'sDiseaseCollaborativeResearchGroup(1993). Anovel gene containing a trinucleotide repeat that is expanded and unstable onHuntington's disease chromosomes.Cell, 72, 971- 83.
67. Jelgersma, G. (1908). Die anatomischen Veränderungen bei Paralysis agitans und chronischer Chorea. Verh. Ges. Dtsch. Naturforsch. Ärzte, 2, 383-8.
68. Kambouris, M., Bohlega, S., AlTahan, A. & Meyer, B.F. (2000). Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am. J. Hum. Genet., 66, 445-52.
69. Kehoe, P., Krawczak, M., Harper, P. S., Owen, M. J. & Jones, A. L. (1999). Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J.Med. Genet., 36, 108-11.
70. Kieburtz, K., MacDonald, M., Shih, C. et al. (1994). Trinucleotide repeat length and progression of illness in Huntington's disease. J.Med. Genet., 31, 872-4.
71. Kirkwood, S. C., Siemers, E., Hodes, M.E., Conneally, P. M., Christian, J. C. & Foroud, T. (2000). Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatry, 69, 773-9.
72. Koller, W. C. & Trimble, J. (1985). The gait abnormality of Huntington's disease. Neurology, 35, 1450-4.
73. Koroshetz, W. J., Jenkins, B. G., Rosen, B. R. & Beal, M. F. (1997). Energy metabolism defects inHuntington's diseaseandeffects of coenzyme Q10. Ann. Neurol., 41, 160-5.
74. Kovtun, I. V. & McMurray, C. T. (2001). Trinucleotide expansion in haploid germ cells by gap repair. Nat. Genet., 27, 407- 11.
75. Kremer, B., Almqvist, E., Theilmann, J. et al. (1995). Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am. J. Hum. Genet., 57, 343-50.
76. Kremer, B., Clark, C. M., Almqvist, E. W. et al. (1999). Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology, 53, 1000-11.
77. Kremer, H. P. & Roos, R. A. (1992). Weight loss in Huntington's disease. Arch. Neurol., 49, 349.
78. Landwehrmeyer, G. B., McNeil, S. M., Dure, L. S. et al. (1995). Huntington's Disease Gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol., 37, 218-30.
79. Lanska, D. J., Lanska, M. J., Lavine, L. & Schoenberg, B. S. (1988). Conditions associated with Huntington's disease at death. A case-control study. Arch. Neurol., 45, 878-80.
80. Lasker, A. G. & Zee, D. S. (1997). Ocular motor abnormalities in Huntington's disease. Vision Res., 37, 3639-45.
81. Lasker, A. G., Zee, D. S., Hain, T. C., Folstein, S. E. & Singer, H. S. (1998). Saccades in Huntington's disease: slowing and dysmetria. Neurology, 38, 427-31.
82. Leeflang, E. P., Zhang, L., Tavare, S. et al. (1995). Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum.Molec. Genet., 4, 1519-26.
83. Li, J. L., Hayden, M. R., Almqvist, E.W. et al. (2003). A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am. J. Hum. Genet., 73, 682-7.
84. Li, S. H., Schilling, G., Young, W.3 et al. (1993). Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron, 11, 985-93.
85. Li, S. H., Cheng, A. L., Zhou, H. et al. (2002). Interaction of Huntington disease protein with transcriptional activator Sp1.Mol. Cell. Biol., 22, 1277-87.
86. Losekoot, M., Bakker, B., Laccone, F., Stenhouse, S. & Elles, R. (1999). A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease. Eur. J. Hum. Genet., 7, 217- 22.
87. Louis, E. D., Marder, K., Moskowitz, C. & Greene, P. (1999). Arm elevation in Huntington's disease: dystonia or levitation? Mov. Disord., 14, 1035-8.
88. Louis, E.D., Anderson, K. E., Moskowitz, C., Thorne, D. Z. & Marder, K. (2000). Dystonia-predominant adult-onsetHuntington disease: association between motor phenotype and age of onset in adults. Arch. Neurol., 57, 1326-30.
89. Lund, J. C. (1860). Chorea St VitusDance in Saetersdalen. In Quoted by Orbeck 1, ed. p. 137.
90. MacMillan, J. C., Snell, R. G., Tyler, A. et al. (1993). Molecular analysis and clinical correlations of theHuntington's disease mutation. Lancet, 342, 954-958.
91. Mahadevan, M., Tsilfidis, C., Sabourin, L. et al. (1992). Myotonic dystrophy mutation: an unstable CTGrepeat in the 3
92. Mandich, P., Di Maria, E., Bellone, E., Ajmar, F. & Abbruzzese, G. (1996). Molecular analysis of the IT15 gene in patients with apparently 'sporadic' Huntington's disease. Eur. Neurol., 36, 348-52.
93. Mangiarini, L., Sathasivam, K., Seller, M. et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
94. Marder, K., Zhao, H., Myers, R. H. et al. (2000). Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology, 54, 452-58.
95. Margolis, R. L., O'Hearn, E., Rosenblatt, A. et al. (2001). A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann. Neurol., 50, 373-80.
96. Mars, H., Lewis, L. A., Robertson, A. L., Jr., Butkus, A. & Williams, G. H., Jr. (1969). Familial hypo-beta-lipoproteinemia: a genetic disorder of lipid metabolism with nervous system involvement. Am. J. Med., 46, 886-900.
97. McComas, A. J., Sica, R. E. & Toyonaga, K. (1978). Incidence, severity, and time-course of motoneurone dysfunction in myotonic dystrophy: their significance for an understanding of anticipation. J. Neurol. Neurosurg. Psychiatry, 41, 882-93.
98. Moore, R. C., Xiang, F., Monaghan, J. et al. (2001). Huntington disease phenocopy is a familial prion disease.Am. J. Hum.Genet., 69, 1385-8.
99. Morales, L. M., Estevez, J., Suarez, H., Villalobos, R., Chacin, D. B. & Bonilla, E. (1989). Nutritionalevaluation ofHuntingtondisease patients. Am. J. Clin. Nutr., 50, 145-50.
100. Myers, R. H., Vonsattel, J. P., Stevens, T. J. et al. (1988). Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology, 38, 341-7.
101. Myers, R. H., Sax, D. S., Koroshetz, W. J. et al. (1991). Factors associated with slowprogression inHuntington's disease. Arch.Neurol., 48, 800-4.
102. Myers, R. H., MacDonald, M. E., Koroshetz, W. J. et al. (1993). De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet., 5, 168-73.
103. Nance, M. A. (1998). Huntington disease: clinical, genetic, and social aspects. J. Geriatr. Psychiatry Neurol., 11, 61-70.
104. Nucifora, F. C., Jr., Sasaki, M., Peters, M. F. et al. (2001). Interference byhuntingtinandatrophin-1withcbp-mediatedtranscription leading to cellular toxicity. Science, 291, 2423-8.
105. Oepen, G., Clarenbach, P. & Thoden, U. (1981). Disturbance of eye movements inHuntington's chorea. Arch. Psychiatr.Nervenkr., 229, 205-13.
106. Panas, M., Avramopoulos, D., Karadima, G., Petersen, M. B. & Vassilopoulos, D. (1999). Apolipoprotein E and presenilin-1 genotypes in Huntington's disease. J. Neurol., 246, 574-7.
107. Panov, A. V., Gutekunst, C.-A., Leavitt, B. et al. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-6.
108. Penney, J.B., Jr., Young, A.B., Shoulson, I. et al. (1990). Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord., 5, 93-9.
109. Penney, J. B., Jr., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. (1997). CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol., 41, 689-92.
110. Perutz, M. (1996). Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol., 6, 848-58.
111. Phillips, J. G., Bradshaw, J. L., Chiu, E., Teasdale, N., Iansek, R. & Bradshaw, J. A. (1996). Bradykinesia and movement precision in Huntington's disease. Neuropsychologia, 34, 1241-45.
112. Pickering, D. S., Thomsen, C., Suzdak, P. D. et al. (1993). A comparison of two alternatively spliced forms of a metabotropic glutamate receptor coupled to phosphoinositide turnover. J. Neurochem., 61, 85-92.
113. Pratley, R. E., Salbe, A. D., Ravussin, E. & Caviness, J. N. (2000). Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol., 47, 64-70.
114. Quinn, N. & Schrag, A. (1998). Huntington's disease and other choreas. J. Neurol., 245, 709-16.
115. Ranen, N., Stine, O., Abbot, M. et al. (1995). Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am. J. Hum. Genet., 57, 593-602.
116. Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B. & Young, A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. Proc. Natl Acad. Sci., USA, 85, 5733-7.
117. Roizin, L., Stellar, S., & Liu, J. (1979). Neuronal nuclear-cytoplasmic changes in Huntingtons chorea: electron microscope investigations. In Advance in Neurology, Huntington's Disease, ed. N. Wexler & A. Barbeau, New York: Raven Press. pp. 195-22.
118. Roos, R. A., Pruyt, J. F., de Vries, J. & Bots, G. T. (1985). Neuronal distribution in the putamen inHuntington's disease. J.Neurol. Neurosurg. Psychiatry, 48, 422-5.
119. Rosenblatt, A., Brinkman, R. R., Liang, K. Y. (2001). Familial influence on age of onset among siblings with Huntington disease. Am. J. Med. Genet., 105, 399-403.
120. Ross, C. A. (2002). Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron, 35, 819-22.
121. Rubinsztein, D. C., Leggo, J., Barton, D. E. & Ferguson-Smith, M. A. (1993). Site of (CCG) polymorphism in the HD gene. Nat. Genet., 5, 214-15.
122. Rubinsztein, D. C., Leggo, J., Coles, R. et al. (1996). Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntingtondisease(HD)generevealsHDcaseswith36repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet., 59, 16-22.
123. Rubinsztein, D. C., Leggo, J., Chiano, M. et al. (1997). Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset ofHuntington disease. Proc.Natl Acad. Sci., USA, 94, 3872-6.
124. Sanberg, P. R., Fibiger, H. C. & Mark, R. F. (1981). Body weight and dietary factors inHuntington's disease patientscomparedwith matched controls.Med. J. Aust. 1, 407-9.
125. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55-66.
126. Schapira, A. H. (1999). Mitochondrial involvement in Parkinson's, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochem. Biophys. Acta, 1410, 99-102.
127. Scherzinger, E., Lurz, R., Turmaine, M. et al. (1997). Huntingtinencoded polyglutamine expansions formamyloid-like protein aggregates in vitro and in vivo. Cell, 90, 549-58.
128. Schilling, G., Sharp, A. H., Loev, S. J. et al. (1995). Expression of the Huntington's disease (IT15) protein product in HD patients. Hum.Mol. Genet., 4, 1365-71.
129. Schubotz, R., Hausmann, L., Kaffarnik, H., Zehner, J. & Oepen, H. (1976). Fatty acid patterns and glucose tolerance in Huntington's chorea. Res. Exp.Med. (Berl.), 167(3), 203-15.
130. Schwarz, M., Fellows, S. J., Schaffrath, C. & Noth, J. (2001). Deficits in sensorimotor control during precise hand movements in Huntington's disease. Clin. Neurophysiol., 112, 95-106.
131. Sharp, A. H., Loev, S. J., Schilling, G. et al. (1995). Widespreadexpression ofHuntington's disease gene (IT15) protein product.Neuron, 14, 1065-74.
132. Shinotoh, H., Calne, D.B., Snow, B. et al. (1994). NormalCAGrepeat length in the Huntington's disease gene in senile chorea. Neurology, 44, 2183-4.
133. Shoulson, I. (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology, 31, 1333-5.
134. Shoulson, I. & Fahn, S. (1979). Huntington disease: clinical care and evaluation. Neurology, 29, 1-3.
135. Shoulson, I., Odoroff, C., Oakes, D. et al. (1989). Acontrolled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol., 25, 252-9.
136. Snell, R. G., MacMillan, J. C., Cheadle, J. P. et al. (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet., 4, 393-7.
137. Snowden, J., Craufurd, D., Griffiths, H., Thompson, J. & Neary, D. (2001). Longitudinal evaluation of cognitive disorder in Huntington's disease. J. Int. Neuropsychol. Soc., 7, 33-44.
138. Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O. et al. (2000). The Huntington's disease protein interacts with p53 and CREBbinding protein and represses transcription. Proc. Natl Acad. Sci., USA, 97, 6763-8.
139. Steffan, J. S., Bodai, L., Pallos, J. et al. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739-43.
140. Tanaka, M., Machida, Y., Niu, S. et al. (2004). Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat.Med., 10, 148-54.
141. Thompson, P. D., Berardelli, A., Rothwell, J. C. et al. (1988). The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain, 111(2), 223-44.
142. Tian, J. R., Zee, D. S., Lasker, A. G. & Folstein, S. E. (1991). Saccades in Huntington's disease: predictive tracking and interaction between release of fixation and initiation of saccades. Neurology, 41, 875-81.
143. Trottier, Y., Biancalana, V. & Mandel, J. L. (1994). Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J.Med. Genet., 31, 377-82.
144. van Vugt, J. P., van Hilten, B. J. & Roos, R. A. (1996). Hypokinesia in Huntington's disease. Mov. Disord., 11, 384-88.
145. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E.D. & Richardson, E., Jr. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-77.
146. Vuillaume, I., Meynieu, P., Schraen-Maschke, S., Destee, A. & Sablonniere, B. (2000). Absence of unidentified CAG repeat expansion in patients with Huntington's disease-like phenotype. J. Neurol. Neurosurg. Psychiatry, 68, 672-5.
147. Waters, C. O. (1842). In Practice in Medicine, ed. R. Dunglison. Philadelphia: Lee and Blanchard. p. 312.
148. Wellington, C. L., Brinkman, R. R., Kusky, J. & Hayden, M. R. (1997). Toward understanding the molecular pathology of Huntington's disease. Brain Pathol., 7, 979-1002.
149. Westphal, C. (1883). Über eine dem Bilde der cerebrospinalen grauen Degeneration ähnlichen Erkrankung des centralen Nervensystems ohne anatomischen Befund, nebst einigen Bemerkungen über paradoxe Contractionen. Arch. Psychiatr. Nervenkr., 14, 187-94.
150. Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. (2002). Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum.Mol. Genet., 11, 2905-17.
151. Young, A.B., Shoulson, I., Penney, J.B. et al. (1986). Huntington's disease in Venezuela: neurologic features and functional decline. Neurology, 36, 244-9.
152. Zeron, M.M., Hansson, O., Chen, N. et al. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron, 33, 849- 60.
153. Zuhlke, C., Riess, O., Schroder, K. et al. (1993). Expansion of the (CAG)n repeat causingHuntington's disease in 352 patients of German origin. Hum.Mol. Genet, 2, 1467-9.